<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6039">
  <stage>Registered</stage>
  <submitdate>9/08/2016</submitdate>
  <approvaldate>9/08/2016</approvaldate>
  <nctid>NCT02864264</nctid>
  <trial_identification>
    <studytitle>Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis</studytitle>
    <scientifictitle>Double-Blind, Randomized, Placebo-Controlled, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Target Engagement of BMS-986184 in Healthy Subjects and to Evaluate the Safety, Efficacy, Pharmacokinetics, Target Engagement, and Pharmacodynamics of BMS-986184 in Patients With Moderate to Severe Ulcerative Colitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-000895-72</secondaryid>
    <secondaryid>IM012-004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986184
Treatment: drugs - Placebo matching BMS-986184

Experimental: Single Ascending Dose (SAD) - IV Panel - Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184

Experimental: Single Ascending Dose (SAD) - SC Panel - Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184

Experimental: Multiple Ascending Dose (MAD) - IV Panel - Multiple IV doses of BMS-986184 or placebo matching BMS-986184

Experimental: Proof of Mechanism (POM) - IV Panel - Multiple IV doses of BMS-986184 or placebo matching BMS-986184


Treatment: drugs: BMS-986184


Treatment: drugs: Placebo matching BMS-986184


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite of safety and tolerability of BMS-986184 as assessed by vital sign measurements</outcome>
      <timepoint>Up to 183 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Composite of safety and tolerability of BMS-986184 as assessed by physical examination findings</outcome>
      <timepoint>Up to 183 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Composite of safety and tolerability of BMS-986184 as assessed by clinical laboratory test results</outcome>
      <timepoint>Up to 183 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Composite of safety and tolerability of BMS-986184 as assessed by Electrocardiogram (ECG) assessments</outcome>
      <timepoint>Up to 183 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Composite of incidence, severity and outcome of all Adverse Events (AEs)</outcome>
      <timepoint>Up to 183 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        

          -  Women of childbearing potential must have a negative serum pregnancy test within 24
             hours prior to the start of study drug

          -  Diagnosis of ulcerative colitis confirmed by endoscopic and histologic evidence (if no
             previous confirmation of diagnosis is available or if diagnosis is not conclusive, at
             time of baseline endoscopy, histology must be performed and read locally to confirm
             diagnosis)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or
             hepatitis C

          -  Subjects with history of cancer, lymphoproliferative disease, class III or IV
             congestive heart failure, myocardial infarction, unstable angina pectoris, or any
             history of significant ocular disease such as glaucoma or retinal disease

        Other protocol defined inclusion/exclusion criteria could apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Screening</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>14/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>7</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>27/09/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Local Institution - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Chisinau</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to determine if single and multiple doses of BMS-986184
      are safe and well tolerated in healthy male and female subjects. The primary purpose of the
      proof of mechanism study is to determine safety and efficacy in patients with ulcerative
      colitis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02864264</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>